Pan-Canadian Lung Cancer Observational Study (PALEOS)

NCT04706754 | Recruiting

• 1 other identifier: PALEOS
• Study Type: observational
• Target: 25,000
• Locations: 1 country
• Sites: 1

Brief Summary

A multicenter, ambispective observational study focusing on patients diagnosed with lung cancer in Canada identified after January 1, 2000 inclusive. This data will be combined with that from deceased patients identified.

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (2)

• Treatment effectiveness

  * To report on the natural history of multiple subgroups of lung cancer patients (regardless of stage) in Canada, from 2000 onwards, using a combination of retrospective and prospective methods that includes diagnostic, molecular alterations, treatment, and outcomes. * To report the real-world treatment patterns of all and specific subgroups of lung cancer patients in Canada, across time (from 2000 onwards), geography. * To recruit from centres that are representative of Canadian patients seen in both academic and community cancer settings.

  Patients will be followed for at least 5 years, for a total of 25 years

• Outcome of Patients

  * To evaluate patient-reported outcomes of different subgroups of lung cancer, through all phases of the disease, from diagnosis through to end-of-life. * To understand the incidence, prevalence, and outcomes (efficacy and toxicity), and patterns of locoregional and metastatic spread of different subgroups of lung cancer. * To understand the evolution of clinical implementation of new diagnostic tests, new biomarker tests, new treatments (whether it be surgical, medical, radiation or other), including access by healthcare teams and patients, their rates of adoption into clinical practice, and retention of over time. * To compare the natural history, stage distribution, treatment outcomes such as treatment effectiveness (composite of disease progression or death) and treatment toxicities (where available) across sub-group of patients with tumors that have been molecularly subtyped and identified to have rare molecular alterations.

  Patients will be followed for at least 5 years, for a total of 25 years

Study Arms (1)

Prospective

Adults aged 18 years or older having a documented lung cancer diagnosis since 2000.

Other: Questionnaires

Interventions

Questionnaires OTHER

Participants will complete the survey(s) at the initial visit and every 3 months and/or whenever there is an update in their treatment protocol. Patients may also choose to opt out of the surveys and only consent to primary data collection at the site.

Prospective

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults aged 18 years or older having a documented lung cancer diagnosis since 2000 from across participating sites/cancer centers across Canada.

You may qualify if:

• Adults aged 18 years or older having a documented lung cancer diagnosis since 2000.

You may not qualify if:

• Patients that decline to provide informed consent.

Sponsors & Collaborators

• William Osler Health System: lead
• Pulse Infoframe: collaborator

Study Sites (1)

Milena (Lynn) Vicente

Brampton, Ontario, L6R 3J7, Canada

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Parneet Cheema, MD

  William Osler Health System

  PRINCIPAL INVESTIGATOR

• Sara Kuruvilla, MD

  London Health Science Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lynn Vicente

CONTACT

4164362556; lynn.vicente@williamoslerhs.ca

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: May 20, 2020
• First Posted: January 13, 2021
• Study Start: April 7, 2020
• Primary Completion (Estimated): April 7, 2040
• Study Completion (Estimated): April 7, 2045
• Last Updated: August 1, 2025

Record last verified: 2025-07

Locations

CA (1)